Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | CCR5 | P51681 | 8/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 3/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1015213 | 0.88 | CCR5 (0.54) | MAOBCCR5SLC6A4KDM4EALDH1A1 | |
| SCHEMBL25180595 | 0.86 | CCR5 (0.57) | MAOBCCR5SLC6A4APPLRRK2 | |
| SCHEMBL30682049 | 0.84 | CCR5 (0.56) | MAOBCCR5SLC6A4ALDH1A1APP | |
| SCHEMBL1549790 | 0.83 | MAOB (0.53) | MAOBCCR5CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL30133848 | 0.82 | CCR5 (0.54) | MAOBCCR5APPLRRK2NPC1 | |
| SCHEMBL30313237 | 0.82 | APP (0.61) | MAOBKDM4ECYP1A2CYP2C9CYP2C19 | |
| SCHEMBL544520 | 0.82 | APP (0.61) | MAOBKDM4ECYP1A2CYP2C9CYP2C19 | |
| SCHEMBL14777550 | 0.82 | NPC1 (0.51) | MAOBKDM4ECYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3931258 | 0.81 | CCR5 (0.56) | MAOBCCR5APPLRRK2NPC1 | |
| SCHEMBL544346 | 0.81 | SLC6A4 (0.54) | MAOBCCR5SLC6A4ALDH1A1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9943519-B2 | Pharmaceutical compounds | GENENTECH, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160152632-A9 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20140309216-A1 | PHARMACEUTICAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-10-16 | — | — | US | disclosed |
| US-8802670-B2 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2014-08-12 | — | — | US | disclosed |
| EP-2402347-A1 | Pharmaceutical compounds | F. Hoffmann-La Roche AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| EP-2041139-B1 | PHARMACEUTICAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2011-11-09 | — | — | EP | disclosed |
| EP-2041139-A2 | PHARMACEUTICAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-04-01 | — | — | EP | disclosed |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIRAMED LIMITED (GB) | 2008-03-27 | — | — | US | disclosed |
| WO-2007127175-A2 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIK3CA, PIK3CD, PIK3CB | MAOB 4312/4885CCR5 4726/4885SLC6A4 3499/4885 |
| US-20140309216-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, AKT3 | MAOB 2218/4885CCR5 3828/4885SLC6A4 2105/4885 |
| US-20160152632-A9 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, AKT3 | MAOB 2218/4885CCR5 3828/4885SLC6A4 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.